The Targeted Genomics portfolio is focussed on meeting the requirements of researchers, clinicians and institutions in the application of cutting edge genomic technologies.
In 2016 TGX completed scoping and proof-of-principle for a new genomics based water test. This was supported by an ICON grant from the ACT government.
As a result of those investigations TGX is now forming an international partnership to field test the technology in 2017 and package it ready to sell into Australia in 2018.
TGx will be looking for further investment to support this development in the first half of 2017.
If you are interested to invest please contact us for more details.